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Abstract
Background: Epigenetic regulators (histone acetyltransferases, methyltransferases, chromatin-
remodelling enzymes, etc) play a fundamental role in the control of gene expression by modifying
the local state of chromatin. However, due to their recent discovery, little is yet known about their
own regulation. This paper addresses this point, focusing on alternative splicing regulation, a
mechanism already known to play an important role in other protein families, e.g. transcription
factors, membrane receptors, etc.
Results: To this end, we compiled the data available on the presence/absence of alternative splicing
for a set of 160 different epigenetic regulators, taking advantage of the relatively large amount of
unexplored data on alternative splicing available in public databases. We found that 49 % (70 % in
human) of these genes express more than one transcript. We then studied their alternative splicing
patterns, focusing on those changes affecting the enzyme's domain composition. In general, we
found that these sequence changes correspond to different mechanisms, either repressing the
enzyme's function (e.g. by creating dominant-negative inhibitors of the functional isoform) or
creating isoforms with new functions.
Conclusion: We conclude that alternative splicing of epigenetic regulators can be an important
tool for the function modulation of these enzymes. Considering that the latter control the
transcriptional state of large sets of genes, we propose that epigenetic regulation of gene
expression is itself strongly regulated by alternative splicing.
Background
Epigenetic regulation of gene expression constitutes a fun-
damental mechanism by which a series of chromatin
modifications allow the normal functioning of the cell
under different conditions [1-3]. In particular, these mod-
ifications control the repressive effect of chromatin, which
limits the access of regulatory proteins to DNA, thus pos-
ing serious restraints to biological processes like replica-
tion, transcription, etc [4]. In agreement with this, an
increasingly large amount of experimental data shows the
relevance of chromatin modifications in development [5],
disease [6], etc. For example, recent studies indicate that
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histone modifications are involved in paternal X chromo-
some inactivation [7,8]. Work from Roopra and col-
leagues [9] shows that histone methylation regulates the
tissue-dependent silencing of neuronal genes. Also,
expression of Hox transcription factors is directly related
to the presence of histone marks [10].
Chromatin modifications are produced by a series of
chromatin-modifying enzymes (epigenetic regulators)
that act on chromatin by either introducing histone mod-
ifications or by inducing ATP-dependent nucleosome
remodelling. Histone modifications usually take place at
histone tails and can introduce a wide variety of covalent
marks including acetylation, methylation, phosphoryla-
tion, etc [2]. These marks provide a simple way to access
nucleosomal DNA and normally have different functional
consequences [2,11-14]. A synthetic view of the biological
role of histone modifications is provided by the histone
code hypothesis [1]. According to this hypothesis, the reg-
ulatory state of a gene is a function of these modifications
and their combinations. Apart from histone-modifying
enzymes, enzymes that utilise ATP to modify the nucleo-
somal structure, altering histone-DNA interactions [15],
also give access to nucleosomal DNA. Interestingly, both
mechanisms are coordinated and cooperate to finally give
access to nucleosomal DNA. For example, it has been
recently shown that the SWI/SNF complex is retained to
the chromatin only if SAGA or NuA4 acetylate it [16].
As with transcription factors [17,18], the functional activ-
ity of chromatin-modifying enzymes must be regulated in
order to produce gene expression patterns that are coher-
ent with high-level biological processes, like development
or tissue differentiation. However, little is yet known
about how this regulation occurs, due to the recent discov-
ery of these enzymes [2,3,19]. Among the possible regula-
tion levels [18], like transcription, translation or mRNA
splicing, in this work we have focused on the study of the
latter. We have chosen alternative splicing for four differ-
ent reasons. First, because recent data [20-23] strongly
suggest that alternative splicing can introduce function-
ally relevant changes in chromatin-modifying enzymes.
Second, because alternative splicing is already known to
play an important role in gene expression regulation by
modulating the functional properties of transcription fac-
tors [17,18], for example, alternative splicing can change
the DNA-binding properties of transcription factors [24];
introduce or eliminate activating domains [25], increase
the in vivo stability of a given isoform [26], etc. Third,
because of the availability, in public databases, of a large
amount of unexplored information on alternative splicing
patterns of chromatin-modifying enzymes is available in
public databases. And fourth, because the functional and
regulatory impact of the most frequent alternative splicing
events -in particular long sequence insertions/deletions- is
relatively easier to infer, particularly if it affects known
protein domains [17].
In our work we have studied (i) whether, and to which
extent, epigenetic regulators (ATP-dependent remodelling
enzymes, histone acetyltransferases, deacetylases, methyl-
transferases, etc) have alternative splicing, and (ii) the
impact of alternative splicing on the domain structure of
these enzymes, with special focus on catalytic and interac-
tion domains, which are known to play a key role
[2,3,27,28]. We obtained the alternative splicing data
from databases with very different curation protocols,
going from literature surveys, like SwissProt [29], to that
of highly automated methods based on sequence process-
ing and EST data, like ENSEMBL [30]. Our results show
that a substantial percentage of epigenetic regulators, 49
% (70 % for human genes), have alternative splicing. In
addition, in more than 59 % of these cases alternative
splicing changes affect either the catalytic or the interac-
tion domain (Figure 1), suggesting the existence of func-
tional regulatory effects comparable to those found in
transcription factors [17].
Results and discussion
A set of 160 genes, from different species, of chromatin-
modifying enzymes was considered in this work. These
enzymes cover the following activities: ATP-dependent
chromatin remodelling, histone acetylation, deacetyla-
tion, methylation, demethylation, phosphorylation,
ubiquitination, and sumoylation. We find (Table 1) that
49 % of the genes show alternative splicing, with an aver-
age number of 2.8 isoforms per gene. In humans, this
number goes up to 70 % (with 2.8 isoforms per gene), a
value close to one of the largest estimates obtained for
human, e.g. 74 % [31]. This result points to a significant
Alternative splicing pattern of human histone methyltrans- ferase SUV39H2 Figure 1
Alternative splicing pattern of human histone meth-
yltransferase SUV39H2. Representation of the domain 
structure of three isoforms of SUV39H2, together with their 
sizes. Shown in red are the two domains, PRE-SET and SET 
that constitute the catalytic unit of the enzyme. The interac-
tion domain, chromodomain, is shown in green. This domain 
is seriously damaged in the second isoform, and is unlikely to 
play any targeting role. The catalytic unit, on the contrary, 
remains intact in this second isoform, but is clearly damaged 
in the third isoform, with 28 % of the SET domain and the 
whole PRE-SET domain missing.BMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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role of alternative splicing in the modulation of the func-
tional properties of chromatin-modifying enzymes.
To characterise the functional variability introduced by
alternative splicing in chromatin-modifying enzymes, we
compared the different isoforms of the same gene at the
protein sequence level, using the longest isoform as a ref-
erence. We focused our study on the changes affecting
protein domains of known function, because they can be
reliably interpreted in terms of biochemical/biological
function [17]. For example, it has been experimentally
shown that domain changes between isoforms can be
associated to isoforms with [17,32]: a dominant-negative
role, different binding affinities or new interaction part-
ners, modified enzymatic activity, etc.
In our case, we observe that 60 % (64 % for human) of the
genes with alternative splicing have isoforms with at least
one missing, or significantly affected, domain (Table 1).
These cases can be grouped according to the functional
role of the domain: (i) changes in the catalytic domains;
(ii) changes in the protein interaction domains; and (iii)
drastic sequence reductions. There are only four excep-
tions to this broad classification, corresponding to the
small, single-domain, human proteins: ubiquitin-conju-
gating enzyme E2A (UBE2A, 154 aas), casein kinase 2,
alpha 1 polypeptide (CKII, 391 aas), NAD-dependent
deacetylase sirtuin-2 (SirT2, 389 aas) and aurora kinase B
(AURKB, 344 aas) for which interaction and catalytic
domains coincide. In these cases, alternative splicing
modifications will affect both functions.
We discuss below the three above-mentioned scenarios.
(i) Changes in the catalytic domains
In the human, we find several genes with isoforms that
have the catalytic domain either missing or affected (Table
2). In a short isoform of the histone methyltransferase
SUV39H2 (Figure 1), the catalytic unit is seriously dam-
aged by the loss of the whole PRESET domain, and about
30 % of the SET domain. The situation seems different for
chromatin remodelling SMARCA1's and kinase PRKDC's
short isoforms, which only lack 11 % and 8 % of their
respective catalytic domains (Table 2). However, visual
inspection of the catalytic domains' structures shows that
the changes are far from being structurally neutral. The
deletion affecting the helicase domain DEXHC of the
chromatin-remodelling enzyme SMARCA1 involves an
alpha helix linking two of the most extreme strands of the
central beta sheet (Figure 2A). The deletion affecting the
catalytic PI3_PI4_KINASE domain of the kinase PRKDC
affects a beta sheet, eliminating one strand and altering
the inter-strand connectivity (Figure 2B). In both cases,
the changes will produce either structural strain, or signif-
icant rearrangements, likely to result in function loss/
modification. Indeed, recent experimental data for kinase
PRKDC [23] show that the protein kinase activity of the
short isoform of this enzyme is lost.
Inactivation of the enzyme's catalytic function by alterna-
tive splicing is also found in one of maize methyltrans-
ferase mez2's isoforms that has completely lost its SET
domain (Table 2).
Two cases deserve additional comment. CARM1 (coacti-
vator-associated arginine methyltransferase 1) has an
alternative splice isoform, the catalytic domain of which,
SKB1, is clearly damaged (48 % of the domain is lost). We
have classed CARM1 within this section, even though an
interaction domain has not yet been identified, because
the full-length isoform is big enough (608 aas) to have
both an interaction domain and a catalytic domain. The
second case is that of RPS6KA5 (ribosomal protein S6
kinase, 90 kDa, polypeptide 5) which has two catalytic
domains, but no interaction domain. In this case, lack of
one of the catalytic domains may result in either an inac-
tive or a less active protein. This situation would be equiv-
alent to an amount regulatory mechanism similar to that
described for other enzymes.
In general, alternative splicing isoforms with a missing
catalytic domain may behave as dominant-negative regu-
lators of the fully functional isoform, a well-known situa-
tion in the case of transcription factors [17,33]. This may
be the case in chromatin-modifying enzymes. Indeed, a
recently described PRKDC isoform with no protein kinase
domain has no catalytic activity and shows slight inhibi-
tory activity of the full-length isoform [23]. However, the
situation may be more complex, as for example the short
PRKDC isoform described here is able to participate in
some DNA repair processes, despite having no kinase
activity [23]. Thus we cannot rule out the possibility that,
in some cases, isoforms lacking the catalytic unit may
have functional roles other than being dominant-negative
regulators.
(ii) Changes in the protein interaction domains
As for the previous case, the effect of alternative splicing
can range from partial deletion to complete domain loss
(Table 3). In the human, we find the latter in several
Table 1: Summary of the data utilised in this work
Number 
of genes
Number of 
genes with AS
Number of genes with 
AS involving protein 
domains
All species 160 78 46
Homo sapiens 71 50 32
Mus musculus 31 21 10BMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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genes, for example GCN5L2, MYST1 and MORF4L1. The
first of them expresses two isoforms lacking the PCAF_N
domain, which is involved in the interaction between the
histone acetyltransferase GCN5L2 and CBP. For histone
acetyltransferase MYST1, the chromodomain is lost
together with a substantial part of the protein, but the cat-
alytic domain is left intact. The case of the histone acetyl-
transferase MORF4L1 is somewhat surprising, as it is the
short isoform that shows the chromodomain, after dele-
tion of a sequence stretch that is in the middle of the
domain's sequence in the long isoform [20].
In other cases the impact caused by alternative splicing
changes is such that, from a functional point of view, it is
essentially equivalent to a domain loss. In general, a sim-
ple measure, like size, is usually enough to understand the
damaging nature of the change. This is the case of human
histone methyltransferase SUV39H2 that has an isoform
with only 68 % of its chromodomain (Figure 1). The del-
eterious effect of this deletion on protein function is sup-
ported by visual inspection of the corresponding domain
structure that points to a disruption of important second-
ary structure elements (Figure 3A). Interestingly, even
small changes are likely to inactivate the domain's func-
tion. For example, chromatin remodelling SMARCA2's
bromodomain only looses 14 % of its residues, but anal-
ysis of the three-dimensional structure shows that a rele-
vant alpha helix from the helix bundle structure is lost,
pointing to a disruption of such a small structure (Figure
3B).
Lack of a whole interaction domain is also found in other
species, for example in the short isoform of the mouse his-
tone acetyltransferase Htatip (Tip60), which has a missing
chromodomain (Table 3). It has to be noted that in this
case a significant part of the protein is also missing (the
short isoform is about half the size of the long isoform).
Thus, while the catalytic domain, MOZ_SAS, is preserved,
it may happen that some unknown domains are also lost.
Interestingly, the case of the human histone acetyltrans-
ferase MORF4L1 also appears in mouse.
Impact of alternative splicing in catalytic domains Figure 2
Impact of alternative splicing in catalytic domains. In 
all cases the part of the protein affected by alternative splic-
ing is shown in yellow, while the remaining of the protein is 
shown in blue. (A) Domain DEXHC of human chromatin 
remodelling SMARCA1. Alternative splicing results in the 
loss of a α-helix. (B) Domain PI3_PI4_KINASE of kinase 
PRKDC. Alternative splicing results in the loss of a sequence 
stretch that has very distant ends. The figures were obtained 
using the MOLSCRIPT software [65].
Table 2: Cases for which alternative splicing sequence changes mainly affect catalytic domains
Gene name Species Reference Isoform Size Alternative Isoform Size Domains affected
SUV39H2 H.s. 410 230 PRESET, SET
SMARCA1 (SNF2L) H.s. 1054 1033 DEXHC
PRKDC (DNA-PK) H.s. 4127 4097 PI3_PI4 KINASE
RPS6KA5 (MSK1) H.s. 802 549 PKINASE
EZH2 H.s. 751 376 SET
EHMT2 (G9a) H.s. 1210 202 ANK, PRESET, SET*
CARM1 (PRMT4) H.s. 608 412 SKB1
SETDB1 H.s. 1290 397 MBD, PRESET, SET, TUDOR
EHMT1 H.s. 1267 1153 SET
FBXL11 (JHDM1A) H.s. 1162 856 JMJC
AOF2 (LSD1) H.s. 876 852 AMINO_OXIDASE
GSG2 (HASPIN) H.s. 798 314 PKINASE
PRDM2 (RIZ1) H.s. 1718 1481 SET
Setdb1 M.m. 1308 488 MBD, PRESET, SET
Htatip M.m 546 492 MOZ_SAS
Fbxl10 (Jhdm1b) M.m. 1309 776 JMJC
Fbxl10 (Jhdm1b) M.m 1309 656 JMJC
Jmjd1b (Jhdm2b) M.m 1562 1124 JMJC
fbxl10 (Jhdm1b) X.l. 1259 738 JMJC
mez2 Z.m. 894 624 SETBMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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In all these cases the a priori functional meaning of the loss
of protein interaction domains is similar and would cor-
respond to a down-regulation of the enzyme's activity.
The underlying molecular mechanisms will vary depend-
ing on the nature of the interaction lost with the missing
domain. If this interaction is required for the formation of
a complex between the enzyme and its partners, necessary
for the catalysis, down-regulation will result from the for-
mation of inactive complexes. This is probably the case of
the short isoform of histone acetyltransferase GCN5L2.
If the missing domain is responsible for substrate target-
ing, e.g. a chromodomain or a bromodomain, down-reg-
ulation will be a consequence of the enzyme being unable
to reach its substrate. However, in this case another option
is also possible, as the enzyme could be recruited to its
reaction site after binding one of its complex's partners.
The resulting effect on the regulation of gene expression
may be substantially different in this case, as modification
of the histone tail will take place. However, lack of the
chromatin-binding domain will eliminate the positive
feedback in chromatin signalling. The latter is mediated
by specific interactions between the modified histone tails
and the corresponding enzymes and leads to self-perpetu-
ation of activating marks on chromatin. This effect has
been recently proposed for enzymes carrying the bromo-
domain [16,34].
Lastly, we also find instances where alternative splicing is
likely to result in small modulatory changes. For example,
in histone methyltransferase MLL only one of the three
PHD domains is affected by alternative splicing. The small
size of the change, 11 % of the domain, and the fact that
the other two PHD domains remain intact, points to a
modulation of the enzyme's binding properties rather
than to a complete inactivation. For C.elegans's histone
acetyltransferase cbp-1, the situation is similar as only one
of the two copies of the protein interaction domain
ZNF_TAZ is affected, by a small change that happens at a
relatively neutral location (Figure 4).
Impact of alternative splicing in interaction domains Figure 3
Impact of alternative splicing in interaction domains. 
In all cases the part of the protein affected by alternative 
splicing is shown in yellow, while the remaining of the protein 
is shown in blue. (A) Chromodomain of human histone 
methyltransferase SUV39H2. One of the main strands of the 
β-sheet is missing in one of the alternative splice isoforms. 
(B) Bromodomain of human chromatin remodelling 
SMARCA2. One of the four helices of the helix bundle is lost 
in the alternative splice isoforms. The figures were obtained 
using the MOLSCRIPT software [65].
Table 3: Cases for which alternative splicing sequence changes mainly affect interaction domains
Gene name Species Reference Isoform Size Alternative Isoform Size Domains affected
SUV39H2 H.s. 410 350 CHROMO
GCN5L2 H.s. 837 476 PCAF_N
GCN5L2 H.s. 837 427 PCAF_N
MYST-1 H.s. 467 300 CHROMO
SMARCA2 (BRM) H.s. 1590 1572 BROMO
MLL H.s. 3969 3931 PHD
MORF4L1 H.s. 362 333 CHROMO
MORF4L1 H.s. 362 323 CHROMO
FBXL10 (JHDM1B) H.s. 1336 1326 LRR_RI
FBXL10 (JHDM1B) H.s. 1336 1306 LRR_RI
JMJD2B (JHDM3B) H.s. 1096 448 PHD, TUDOR
MLL2 H.s. 5265 4957 RING, PHD
MLL3 H.s. 4911 4029 PHD
NSD1 H.s. 2696 2593 PWWP
RNF40 H.s. 1001 838 RING, ZF_C3HC4
Morf4l1 M.m. 362 323 CHROMO
Htatip M.m. 546 302 CHROMO
Fbxl11 (Jhdm1a) M.m. 1161 494 ZF_CXXC
Fbxl11 (Jhdm1a) M.m. 1161 338 ZF_CXXC
Jmjd2a (Jhdm3a) M.m. 1064 1033 PHD, TUDOR
Jmjd2b (Jhdm3b) M.m. 1086 1021 TUDOR
cbp-1 C.e. 2056 2045 ZNF_TAZBMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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(iii) Drastic sequence changes
Generation of inactive isoforms constitutes a simple and
powerful mechanism to regulate the amount of functional
protein present in the cell [35-37]. Usually, inactive iso-
forms are short versions of the fully active protein in
which most functional domains are missing [36]. For sev-
eral genes we find isoforms that fit this description and
thus could be inactive isoforms (Table 4). In all of them
the size reduction relative to the active protein is dramatic,
between 35 % and 95 %, and most of the functional
domains are lost or seriously damaged. For example, in
the case of the human kinase ATM, the functional protein
is 3056 residues long, whilst there is a short isoform asso-
ciated to this gene with only 138 residues (Table 4). Catal-
ysis-associated domains like FAT, FATC and
PI3_PI4_KINASE, are missing from the short isoform,
together with most of the non-annotated parts of the
sequence. It is improbable that such isoform may have
any functional role itself and is thus likely to be the result
of the above-mentioned regulatory process. We observe a
similar situation for ubiquitin-conjugating enzyme E2 A
(UBE2A), which has two isoforms lacking 47 % and 22 %
of the UBCC domain. The damaging effect of the missing
sequence is supported by visual inspection of the corre-
sponding domain structures (Figure 5).
It has to be noted, however, that short isoforms may not
always be the consequence of a regulatory process aiming
at reducing the amount of functional protein. In some
genes, for example in the case ankyrin-3 [38], they have a
specific functional role. This could also be the case for
some of the transcripts mentioned in this section.
Furthermore, we cannot completely discard the possibil-
ity that some of these cases correspond to database anno-
tation errors.
Table 4: Cases for which alternative splicing sequence changes result in drastically affected isoforms
Gene name Species Reference Isoform Size Alternative Isoform Size Domains affected
SETDB1 H.s. 1290 249 MBD, PRESET, SET, TUDOR
SETDB1 H.s. 1290 151 MBD, PRESET, SET, TUDOR
SMARCA2 (BRM) H.s. 1590 278 HSA, BRK, DEXHC, HELICASE_C, BROMO
SMARCA2 (BRM) H.s. 1590 254 HSA, BRK, DEXHC, HELICASE_C, BROMO
SMARCA2 (BRM) H.s. 1590 236 HSA, BRK, DEXHC, HELICASE_C, BROMO
SMARCA2 (BRM) H.s. 1590 119 HSA, BRK, DEXHC, HELICASE_C, BROMO
SMARCA4 (BRG1) H.s. 1679 628 BRK, BROMO, DEXHC, HSA
SUV39H1 H.s. 412 409 CHROMO, PRESET, SET
MLL H.s. 3969 511 BROMO, FYRC, FYRN, PHD, SET, ZF-CXXC
ATM H.s. 3056 138 FAT, FATC, PI3_PI4 KINASE
MORF4L1 H.s. 362 235 MRG
EHMT1 H.s. 1267 825 ANK, PRESET, SET
WBP7 (MLL4) H.s. 2715 582 ZF_CXXC, PHD, FYRC, FYRN, SET
Setdb1 M.m. 1308 500 MBD, PRESET, TUDOR
Stk4 M.m. 487 126 PKINASE
Htatip M.m. 546 302 CHROMO
Suv39h2 M.m. 477 257 CHROMO, PRESET, SET
Fbxl10 (Jhdm1b) M.m. 1309 114 JMJC, ZF_CXXC
Su(var)3–9 D.m. 635 475 CHROMO, PRESET, SET
mez2 Z.m. 894 341 SET
In the "Gene name" column we list the standard names of the proteins, although in some cases we also provide alternative names that are 
frequently used in the literature. In the "Species" column H.s., M.m., D.m., C.e., O.s., X.l. and Z.m. mean Homo sapiens, Mus musculus, Drosophila 
melanogaster, Caenorhabditis elegans, Oryza sativa, Xenopus laevis and Zea mays, respectively. The sizes of the different isoforms are given in amino 
acid number. *In this case, although the ANK protein interaction domain is lost, the NFSP transcription factor binding domain is retained.
Impact of alternative splicing in the ZNFTAZ domain of C.ele- gans's histone acetyltransferase cbp-1 Figure 4
Impact of alternative splicing in the ZNFTAZ domain 
of C.elegans's histone acetyltransferase cbp-1. A small 
strand (yellow) is lost in one of the alternative splice isoform. 
Only small changes can be expected from this deletion. The 
figure was obtained using the MOLSCRIPT software [65].BMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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Conclusion
A common effect of alternative splicing is to produce iso-
forms lacking a given functional domain, pointing to an
inhibitory role of the fully functional isoforms [17,36,39].
This correspondence between alternative splicing and
protein function changes is a consequence of the modular
structure of protein function, having been experimentally
demonstrated in different instances [17]. Here we show
that epigenetic regulators are no exception and that their
alternative splicing patterns usually involve loss of the cat-
alytic or the binding domain, resulting in short isoforms
that could easily play the above-mentioned inhibitory
role. They can also be the consequence of alternative splic-
ing-based mechanisms for the regulation of product
amount.
Thus, our results show how alternative splicing may regu-
late the functional role of chromatin-modifying enzymes.
This is a first step towards the goal of understanding the
biological impact of alternative splicing on epigenetic
gene expression regulation. This goal, which in general is
very difficult to attain [17], becomes particularly hard in
our case, as epigenetic regulators act both at gene-specific
and whole-genome levels [2,40]. They are involved in rel-
evant biological processes like development [5] or disease
[6] and, in addition, they may also act on proteins other
than histones. Nonetheless, our results clearly support the
idea that alternative splicing is likely to have a substantial
impact on the epigenetic regulation of large sets of genes,
by regulating the activity of chromatin-modifying
enzymes. One of the simplest mechanisms would be the
co-expression of two alternative splice isoforms of one of
these enzymes, a fully functional isoform and a domi-
nant-negative inhibitor of the former, which may result in
a reduced repression or activation of the set of genes con-
trolled by this enzyme. To illustrate how this could hap-
pen, we can mention the case of G9a (EHMT2), a histone
dimethyltransferase likely to play an important role in the
repression of a large set of neuronal genes [9]. This repres-
sion, which can affect between 30 and 800 genes, is based
on a chromatin-level mechanism [9] (Figure 6): (i) NFSP
transcription factor would recruit histone dimethyltrans-
ferase G9a to the target genes; (ii) the latter would be
silenced by G9a's dymethylation of histone tails at that
location. It has been observed, that dominant-negative
inhibition of G9a results in abrogation of this gene silenc-
ing [9]. In our case, we find that one of the G9a's isoforms
has all the characteristics of a dominant-negative regulator
(Table 2), as it has lost all its domains but the binding
domain to NFSP transcription factor. We can speculate
that this isoform could modulate the repression of this set
of neuronal genes, in a similar way as G9a dominant-neg-
ative designed constructs [9] (Figure 6).
Methods
Dataset of epigenetic regulators
The list of chromatin-modifying enzymes was taken from
five recent reviews on chromatin-modifying enzymes
[2,3,19,41,42]. Note that DNA methyltransferases have
not been considered. Subsequently we checked for the
existence of alternative splicing for the corresponding
genes in different databases: SwissProt [29], NCBI-Gene
[43], Ensembl [44] and ASAP [45]. These databases have
different annotation protocols, from manual annotation
in SwissProt [29] to highly automatic procedures in
Ensembl [44]. This allows increasing the coverage of our
study. A discussion on possible error sources can be found
at the end of the Materials and Methods section.
As shown in Table 5, the final dataset was constituted by
78 genes with alternative splicing, together with addi-
tional information on the species, protein name and func-
tion. Due to the different procedures followed in the
different databases to obtain alternative splicing informa-
tion we expect a complementary coverage of the alterna-
tive splicing patterns.
In general, the gene names used follow the international
standards set for each species. Standard gene names were
obtained: for human from the Human Gene Nomencla-
ture Database [46]; for mouse from the Mouse Genome
Database (MGD) [47]; for D.melanogaster from the Fly-
Base [48], version FB2006_01; for C.elegans  from the
Alternative splicing of human ubiquitin-conjugating enzyme  E2 A UBE2A Figure 5
Alternative splicing of human ubiquitin-conjugating 
enzyme E2 A UBE2A. The part of the protein affected by 
alternative splicing is shown in yellow, and the remaining in 
blue. One can see that a α-helix and a whole β-sheet are lost 
in one of the isoforms, with a potentially very disruptive 
effect. The figure was obtained using the MOLSCRIPT soft-
ware [65].BMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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WormBase [49], release WS166; for Z.mays  from
MaizeGDB [50].
The detailed exon structure of the isoforms studied in this
work is provided in an additional file [see Additional file
ExonStructure.xls].
Possible error sources
As explained in the previous section, alternative splicing
data are obtained from different databases and come from
different sources -e.g. literature, processing of ESTs- there-
fore they will have a different error attached to them.
Unfortunately, it is not possible to provide a reliability
measure for each observation, but we can discuss the reli-
ability of the general trends observed and how the possi-
ble sources of error affect the main conclusions of our
work.
First, we observe that the overall trends we find in our
dataset coincide with those previously observed by other
authors that have studied alternative splicing in more gen-
eral sets of genes. In particular, the fact that insertions/
deletions of domain size prevail in our dataset is in agree-
ment with previous observations [39]. Also the corre-
sponding mechanisms for function modulation -
dominant-negative inhibition, amount regulation- have
been proposed and observed for other genes [17],
although the biological context and expected impact are
obviously different. Some of the very short isoforms we
have obtained can be artifactual but they may also consti-
Hypothetical mechanism of regulation by alternative splicing of histone dimethyltransferase G9a function Figure 6
Hypothetical mechanism of regulation by alternative splicing of histone dimethyltransferase G9a function. (A) 
Experimental evidence indicates that histone dimethyltransferase G9a plays an important role in the silencing of neuronal genes 
in non-neuronal tissues [9]. In the proposed mechanism [9], shown here with red arrows, in non-neuronal tissues the tran-
scription factor NFSP (shown in magenta) recruits the fully functional isoform of G9a (shown here with two domains: a binding 
domain in blue, and a catalytic domain in yellow) to a series of target genes that are subsequently silenced by G9a dimethylation 
of lysine-9 from histone H3. This mechanism may be inhibited/modulated by expression of the G9a short isoform (which only 
retains the NFSP transcription factor binding domain, Table 2), as shown here with green arrows. This isoform may behave as 
a dominant-negative inhibitor, as shown by the green arrows, blocking the access of the catalytically active isoform to the chro-
matin of the target gene. Absence of methylation marks in histone H3's lysine-9 would then result in an active gene. (B) The 
expression state of the target genes in both the nervous system (active, green colour) and in other tissues (silenced, red col-
our), as a result of the silencing, combined, action of NFSP and G9a. Co-expression of both the long and the short isoforms 
may result in the modification of the expression state of the target genes in non-neuronal tissues. These target genes may now 
show varying degrees of activity, as a result of the dominant-negative inhibitor role played by the short isoform (described in 
(A)).BMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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Table 5: List of genes showing alternative splicing
Gene Symbol Species Function Protein name
CDY-1 H.s. A chromodomain protein, Y-linked, 1
GCN5L2 H.s. A GCN5 general control of amino-acid synthesis 5-like 2 (yeast)
HAT1 H.s. A histone acetyltransferase 1
HTATIP (TIP60) H.s. A HIV-1 Tat interacting protein
MORF4L1 H.s. A mortality factor 4 like 1
MYST1 H.s. A MYST histone acetyltransferase 1
NCOA-1 H.s. A Nuclear receptor coactivator 1
TAF1 (TAF250) H.s. A TATA box binding protein (TBP)-associated factor, 250 kDa
CARM1 (PRMT4) H.s. M coactivator-associated arginine methyltransferase 1
DOT1L H.s. M DOT1-like, histone H3 methyltransferase (S. cerevisiae)
EHMT2 (G9a) H.s. M euchromatic histone-lysine N-methyltransferase 2
EZH2 H.s. M enhancer of zeste homolog 2 (Drosophila)
MLL H.s. M Myeloid/lymphoid or mixed-lineage leukemia
PRMT1 H.s. M protein arginine methyltransferase 1
SETD8 (PR-SET7, SET8) H.s. M SET domain containing (lysine methyltransferase) 8
SETDB1 H.s. M SET domain, bifurcated 1
SUV39H1 H.s. M suppressor of variegation 3–9 homolog 1 (Drosophila)
SUV39H2 H.s. M suppressor of variegation 3–9 homolog 2 (Drosophila)
ATM H.s. P ataxia telangiectasia mutated
ATR H.s. P ataxia telangiectasia and Rad3 related
AURKB H.s. P aurora kinase B
MAP3K12 (DLK/ZIP) H.s. P Mitogen-activated protein kinase 12
PRKDC (DNA-PK) H.s. P protein kinase, DNA-activated, catalytic polypeptide
RPS6KA5 (MSK1) H.s. P ribosomal protein S6 kinase, 90kDa, polypeptide 5
RPS6KA4 (MSK2) H.s. P ribosomal protein S6 kinase, 90kDa, polypeptide 4
CHD-3 H.s. R chromodomain helicase DNA binding protein 3
CHD-4 H.s. R chromodomain helicase DNA binding protein 4
SMARCA1 (SNF2L) H.s. R SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1
SMARCA2 (BRM) H.s. R SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2
SMARCA4 (BRG1) H.s. R SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
UBE2A H.s. U ubiquitin-conjugating enzyme E2A (RAD6 homolog)
CKII H.s. P casein kinase 2, alpha 1 polypeptide
EHMT1 H.s. M Histone-lysine N-methyltransferase, H3 lysine-9 specific 5
GSG2 (HASPIN) H.s. P Serine/threonine-protein kinase Haspin
FBXL11 (JHDM1A) H.s. DM JmjC domain-containing histone demethylation protein 1A
FBXL10 (JHDM1B) H.s. DM JmjC domain-containing histone demethylation protein 1B
JMJD1B (JHDM2B) H.s. DM JmjC domain-containing histone demethylation protein 2B
JMJD2B (JHDM3B) H.s. DM JmjC domain-containing histone demethylation protein 3B
JMJD2C (JHDM3C) H.s. DM JmjC domain-containing histone demethylation protein 3C
AOF2 (LSD1) H.s. DM Lysine-specific histone demethylase 1
MLL2 H.s. M Myeloid/lymphoid or mixed-lineage leukemia protein 2 (ALL1-related protein)
MLL3 H.s. M Myeloid/lymphoid or mixed-lineage leukemia protein 3 homolog
WBP7 (MLL4) H.s. M WW domain-binding protein 7 (Myeloid/lymphoid or mixed-lineage leukemia protein 4) (Trithorax 
homolog 2)
MLL5 H.s. M myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila)
NSD1 H.s. M H3-K36-HMTase and H4-K20-HMTase
PRMT5 H.s. M Protein arginine N-methyltransferase 5
PRDM2 (RIZ1) H.s. M PRDM2 (PR domain containing 2, with ZNF domain)
RNF40 H.s. U E3 ubiquitin-protein ligase BRE1B (RING finger protein 40)
SETDB2 H.s. M Histone-lysine N-methyltransferase SETDB2
SIRT2 H.s. DA NAD-dependent deacetylase sirtuin-2
Gtf3c4 M.m. A General transcription factor IIIC, polypeptide 4
Htatip M.m. A HIV-1 tat interactive protein, homolog (human)
Morf4l1 M.m. A mortality factor 4 like 1
Ncoa-1 M.m. A Nuclear receptor coactivator 1
Ehmt2 M.m. M euchromatic histone lysine N-methyltransferase 2
Ezh2 M.m. M enhancer of zeste homolog 2 (Drosophila)
Prmt1 M.m. M protein arginine N-methyltransferase 1
Carm1 (Prmt4) M.m. M protein arginine N-methyltransferase 4
Setdb1 M.m. M SET domain, bifurcated 1BMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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tute a possible regulatory mechanism [51]. In fact very
short isoforms have been described for the genes in our
study, e.g. for MLL [52].
At a more detailed level, in the case of data from ASAP
[45], the authors provide an error estimate of less than 2
% [53]. To decrease it more, we discarded all the ASAP iso-
forms for a given gene, when none of them coincided with
the longest isoform provided by another database. For the
remaining databases the error estimates will vary, even
within the database. For example, in the case of SwissProt
[29], protein records are manually annotated, but the evi-
dence supporting a given isoform may vary from one gene
to another. Nonetheless, SwissProt [29] has been utilised
in many bioinformatics studies on alternative splicing due
to the high quality of the data [39,54-59]. In the case of
Ensembl [44], the predictive nature of the annotations
suggests that there may be a certain amount of false posi-
tives. The latter may be more frequent in the case of very
short isoforms, although it has to be mentioned that these
isoforms are usually supported by a substantial amount of
evidence from EST data and other databases.
For all these reasons, we believe that the overall conclu-
sions of this work will not be substantially affected by pos-
sible errors in the data.
Domain annotation
The domain structure of the different isoforms was
obtained utilising CD-Search [60]. This program identi-
fies the functional domains present in a protein sequence.
We focused our analysis on the Pfam [61] and Smart [62]
domain definitions. COG (Tatusov et al., 2001) defini-
tions were not available for all the species and for this rea-
son they were not utilised (no significant differences were
observed when utilised in this analysis). Because in some
cases domain boundaries for the same domain would
change slightly from one database to another, we com-
bined the two definitions in a consensus domain defini-
tion, as follows: the location of the N-terminal domain
was taken to be the minimum of the Pfam [61] and Smart
[62] values; for the C-terminal end, instead of the mini-
mum, we took the maximum of the Pfam [61] and Smart
[62] values. For example, if a given domain occupies posi-
tions 3–75 and 8–82 according to the Pfam and Smart
definitions, respectively, in our consensus definition it
will go from position 3 to position 82.
We eliminated from the domain mapping all the domains
with functional annotations of no, or unclear, meaning
within the context of this work, that is: microbial
domains, like viral capsid domains, and Pfam B domains
[61]. In Table 6 we provide a list of the domains affected
by alternative splicing mentioned in this work.
Classification of the alternative splicing events
Our study focused on those alternative splicing events that
affect any of the known domains, as it is easier to infer
their functional impact [17]. In general, epigenetic regula-
tors are multidomain proteins that have both catalytic
and interaction domains. Because the functional role of a
given isoform will depend on which of these domains has
been affected by alternative splicing, we grouped the
observed isoforms according to the biochemical nature of
the affected domain(s): (i) alternative splicing affects the
catalytic domains; (ii) alternative splicing affects the pro-
tein interaction domains; and (iii) alternative splicing
affects results in drastic sequence reductions. An alterna-
Suv39h1 M.m. M suppressor of variegation 3–9 homolog 1 (Drosophila)
Suv39h2 M.m. M suppressor of variegation 3–9 homolog 2 (Drosophila)
Stk4 M.m. P serine/threonine kinase 4
Myst2 (Hbo1) M.m. A Histone acetyltransferase MYST2
Fbxl11 (Jhdm1a) M.m. DM JmjC domain-containing histone demethylation protein 1A
Fbxl10 (Jhdm1b) M.m. DM JmjC domain-containing histone demethylation protein 1B
Jmjd1a (Jhdm2a) M.m. DM JmjC domain-containing histone demethylation protein 2A
Jmjd1b (Jhdm2b) M.m. DM JmjC domain-containing histone demethylation protein 2B
Jmjd2a (Jhdm3a) M.m. DM JmjC domain-containing histone demethylation protein 3A
Jmjd2b (Jhdm3b) M.m. DM JmjC domain-containing histone demethylation protein 3B
Ring1A M.m. U E3 ubiquitin-protein ligase RING1
Rnf20 M.m. U E3 ubiquitin-protein ligase BRE1A
Su(var)3–9 D.m. M Suppressor of variegation 3–9
trx D.m. M trithorax
Taf1 D.m. P TBP-associated factor 1
brm D.m. R Brahma
cbp-1 C.e. A Bromodomain
fbxl10 (jhdm1b) X.l. DM JmjC domain-containing histone demethylation protein 1B
mez2 Z.m. M Polycomb protein EZ2
In the "Species" column H.s., M.m., C.e., O.s., X.l. and Z.m. mean Homo sapiens, Mus musculus, Caenorhabditis elegans, Oryza sativa, Xenopus laevis and 
Zea mays, respectively. In the column "Function" A, DA, DM, M, P, U and R mean Acetylation, deacetylation, demethylation, methylation, 
phosphorylation, ubiquitination and chromatin remodelling, respectively.
Table 5: List of genes showing alternative splicing (Continued)BMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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Table 7: Templates utilised for comparative modelling
Protein name Size Ref. Species Domain name PDB code % Seq. Id.
cbp-1 2056 C.e. ZNF_TAZ 1L8C 75
SMARCA1 (SNF2L) 1054 H.s. DEXHC 1Z6A 38
SMARCA2 (BRM) 1590 H.s. BROMO 1N72 26
SUV39H2 410 H.s. CHROMO 1KNA 47
SUV39H2 410 H.s. SET 1MVH 39
UBE2A 154 H.s. UBCC 1JAS 95
PRKDC (DNA-PK) 4127 H.s. PI3-PI4 KINASE 1E8Y 29
In the "Species" column H.s. and C.e., mean Homo sapiens and Caenorhabditis elegans, respectively. The size of the whole protein is given in amino 
acid number. % Seq.Id. is the percentage of sequence identity between the target and the template sequences. The PDB code is the code of the 
template structure utilised for the comparative modelling in the PDB database [64].
Table 6: List of domains affected by alternative splicing in chromatin-modifying enzymes
Domain name Function Enzyme name
AMINO_OXIDASE Catalytic AOF2
ANK Protein-Protein Interaction EHMT1, EHMT2
BRK Unknown SMARCA2, SMARCA4
BROMO Interaction (Acetylated Lysines) SMARCA2, SMARCA4, MLL
CHROMO Interaction (Methylated Lysines) SUV39H1, SUV39H2, Suv39h2, Su(var)3–9, MYST-1, MORF4L1, Morf4l1, Htatip
DEXHC Catalytic SMARCA1, SMARCA2, SMARCA4
FAT Interaction/Modulate catalysis ATM
FATC Interaction/Modulate catalysis ATM
FYRC Probably not-catalytic MLL, WBP7
FYRN Probably not-catalytic MLL, WBP7
HELICASE_C SMARCA2
HSA Probably DNA binding SMARCA2, SMARCA4
JMJC Catalytic FBXL11, fbxl10 (from Mus musculus and Xenopus laevis), jmjd1b
LRR_RI Interaction FBXL10
MBD DNA binding SETDB1, Setdb1
MOZ_SAS Catalytic Htatip
MRG Interaction MORF4L1
PCAF_N Interaction with CBP GCN5L2
PHD Intra- and Intermolecular interactions MLL, MLL2, MLL3, JMJD2B, Jmjd2a, WBP7
PI3_PI4_KINASE Catalytic PRKDC, ATM
PKINASE Catalytic AURKB, GSG2, RPS6KA5, stk4
PRESET Interaction-Catalysis SUV39H1, SUV39H2, Suv39h2, Su(var)3–9, SETDB1, Setdb1, EHMT1, EHMT2
PWWP Unknown NSD1
RING Interaction MLL2, RNF40
SET Catalytic PRDM2, SUV39H1, SUV39H2, suv39h2, Su(var)3–9,SETDB1, Setdb1, mez2, MLL, 
WBP7, EHMT1, EHMT2, EZH2
SKB1 Catalytic CARM1
UBCC Whole protein UBE2A
TUDOR Interaction Jmjd2a, Jmjd2b, JMJD2B, SETDB1, Setdb1
ZF_C3HC4 Interaction RNF40
ZF_CXXC Interaction Fbxl10, Fbxl11, MLL, WBP7,
ZNF_TAZ Interaction cbp-1BMC Genomics 2007, 8:252 http://www.biomedcentral.com/1471-2164/8/252
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tive splicing event belongs to the first class when the cor-
responding sequence change mainly affects the catalytic
domains, but the resulting isoform retains at least one of
its binding domains (i.e. keeps its binding ability). Alter-
native splicing events are classified in the second group
when the sequence change mainly affects the interaction
domains, but not the catalytic unit. Finally, alternative
splicing events belong to the third class when both the cat-
alytic and the binding domains are affected by the
sequence change. Four proteins were not included in this
classification, ubiquitin-conjugating enzyme E2A
(UBE2A, 154 aas), casein kinase 2, alpha 1 polypeptide
(CKII, 391 aas), NAD-dependent deacetylase sirtuin-2
(SirT2, 389 aas) and aurora kinase B (AURKB, 344 aas)
because they only have a single domain which plays both
a catalytic and a binding role and therefore large alterna-
tive splicing sequence changes are very likely to affect both
functions simultaneously.
Structure analysis
Direct structural information was not available for none
of the proteins considered in this work. However, in some
cases the changes produced by alternative splicing
embraced a part of the sequence for which structural
information was available from a homolog. In these cases,
this part was modelled utilising the well known, standard,
modelling package MODELLER [63], and using the struc-
ture of the homolog as a template. The latter was obtained
from the PDB database [64]. A list of cases, together with
the domains involved, the homologs utilised, and the
sequence identities between the latter and our proteins, is
shown in Table 7.
Structural models are utilised throughout the article to
illustrate the location of alternative splicing changes and
to help understand/infer their functional impact. The con-
clusions that can be drawn from the use of these models
are limited by the following facts: (i) in general, epigenetic
regulators are multidomain proteins, while the structures
correspond to only one of these domains; (ii) the struc-
tural changes resulting from certain sequence changes
may be difficult to predict. It is clear that the structural
analysis would benefit from taking into account the struc-
ture of the whole protein, but this information is not yet
available for the proteins in our dataset or for their
homologs, neither close nor remote. This would be a seri-
ous problem if our aim were to predict with high accuracy
the structural/functional changes resulting from alterna-
tive splicing. However, our goal is more coarse-grained, as
what we want to see is whether alternative splicing
changes result in the presence or absence of the biochem-
ical function associated to a given domain. When the
sequence change affects the whole domain, by far the
most frequent situation, it is reasonable to assume that
the resulting protein has lost this activity and that it may
function as a regulator (e.g. a dominant-negative inhibi-
tor) of the full-length isoform, something that has been
experimentally confirmed in the case of transcription fac-
tors [17], among others.
If the sequence change does not reach the domain size the
situation is more complex, because it is more difficult to
decide whether it will result in complete function loss,
modulation of an original function or creation of a new
function. Without further structural data we cannot pro-
vide a definite answer for none of our cases. However, in
some instances the nature of the sequence change is not
compatible with preservation, or smooth modulation, of
the domain's function. This happens when the domain is
small and the sequence change is large, or it affects the
protein core or any important secondary structure ele-
ment. In these cases we have proposed that the most likely
effect of alternative splicing is that of a regulator of the
fully functional isoforms, something that has been
already observed in the case of the epigenetic regulator
SMARCA1 [22].
Finally, we cannot reject the possibility that some of the
regions affected by alternative splicing may be intrinsi-
cally disordered, as has been recently proposed [59].
However, if the sequence stretch affected by alternative
splicing encompasses a whole protein domain the func-
tional interpretation will remain the same, as it is inde-
pendent of whether the domain in question is structured
or disordered. If the affected stretch is of sub-domain size,
the situation could be different if we knew that the
domain involved is disordered. However, this is unlikely
as the domains affected by alternative splicing discussed
here are homologues, sometimes very close, of domains
with known three-dimensional structure (Table 7).
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Exon structure of the isoforms studied. The file provides a description of 
the exon structure of the isoforms analysed in the present article (Table 2). 
Most of the data were obtained after querying the ENSEMBL [44] and 
NCBI Gene databases [43]. Part of the data were also obtained after 
aligning the target isoform with the genome of the corresponding species 
or using the SEDB package [66]. Finally, in four cases (GSG2, Jmjdb1, 
fbxl10 and mez2, from human, mouse, frog and maize, respectively) no 
information could be retrieved. The structure of the file is the following: 
the first column corresponds to the name of the genes; the second column 
corresponds to the isoform size; the third column corresponds to the organ-
ism; and the following columns correspond to the exons constituting the 
isoform. Each gene is preceded by a line with these fields and the order of 
each exon within the gene (exons with no order number correspond to 
parts of the isoform sequence for which the exon could not be identified). 
For each gene the data given in the first line correspond to the longest, full-
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